Moody Aldrich Partners LLC Reduces Stock Position in Teladoc Health Inc (NYSE:TDOC)

Moody Aldrich Partners LLC lowered its stake in Teladoc Health Inc (NYSE:TDOC) by 96.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,228 shares of the health services provider’s stock after selling 29,166 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Teladoc Health were worth $234,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. PrairieView Partners LLC purchased a new stake in Teladoc Health in the first quarter worth approximately $31,000. Pathstone Family Office LLC bought a new stake in shares of Teladoc Health during the 1st quarter valued at $31,000. Capital Advisory Group Advisory Services LLC bought a new stake in shares of Teladoc Health during the 1st quarter valued at $36,000. Prime Capital Investment Advisors LLC bought a new stake in shares of Teladoc Health during the 1st quarter valued at $37,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Teladoc Health during the 1st quarter valued at $39,000. Institutional investors own 97.14% of the company’s stock.

In other news, CEO Jason N. Gorevic sold 40,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $170.26, for a total value of $6,810,400.00. Following the sale, the chief executive officer now directly owns 711,283 shares in the company, valued at approximately $121,103,043.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO David William Sides sold 3,117 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $216.67, for a total transaction of $675,360.39. Following the completion of the sale, the chief operating officer now owns 7,299 shares in the company, valued at $1,581,474.33. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,977 shares of company stock worth $36,248,032. Insiders own 3.42% of the company’s stock.

TDOC stock traded up $0.56 during mid-day trading on Friday, hitting $237.63. The company had a trading volume of 2,480,093 shares, compared to its average volume of 1,688,738. Teladoc Health Inc has a 12-month low of $54.58 and a 12-month high of $240.00. The company has a quick ratio of 6.14, a current ratio of 6.14 and a debt-to-equity ratio of 0.45. The company has a 50-day moving average price of $207.13 and a 200 day moving average price of $158.76.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.11). The company had revenue of $241.03 million during the quarter, compared to analysts’ expectations of $220.49 million. Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. The firm’s revenue for the quarter was up 85.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.41) EPS. Analysts predict that Teladoc Health Inc will post -1.41 EPS for the current fiscal year.

A number of brokerages have recently issued reports on TDOC. Wells Fargo & Co boosted their price objective on shares of Teladoc Health from $135.00 to $175.00 in a research report on Thursday. ValuEngine downgraded shares of Teladoc Health from a “buy” rating to a “hold” rating in a research report on Friday, May 1st. Royal Bank of Canada boosted their price objective on shares of Teladoc Health from $200.00 to $235.00 and gave the company an “outperform” rating in a research report on Thursday. Canaccord Genuity boosted their price objective on shares of Teladoc Health from $195.00 to $255.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Argus started coverage on shares of Teladoc Health in a research note on Monday, July 13th. They set a “buy” rating and a $280.00 target price on the stock. Fifteen equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $195.04.

Teladoc Health Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Story: Market Timing

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.